3TR is the largest IMI project yet, focussing on autoimmune, inflammatory and allergic diseases including COPD and asthma. The project aims to provide insights into mechanisms of response and non-response to treatment across different diseases.
The EU provides opportunities and funding for public health and medical research across Europe. We work to ensure that people with lung conditions and the general public have the opportunity to influence research and guidelines at the European level.
One way of achieving this is through participation in EU-funded research projects, in which we advocate for patient involvement, from project design to dissemination.
ELF is primarily interested in pan-European collaboration initiatives, with scope for improving the lives of people with respiratory conditions with tangible outcomes. Our goal in EU projects is twofold:
ELF is motivated to involve patients in all stages of EU projects. Involvement of those with expertise in living with a condition in research study design, on ethics boards and patient input groups can help ensure that recruitment targets are met and that the patients taking part in research can have a positive experience, that real-world outcomes are achieved by the project, appropriate communication and dissemination of the project to key stakeholders outside of the respiratory professional community and a legacy for the project.
If you are interested in involving ELF in an EU project, please read through all of the information below and submit a proposal form to info@europeanlung.org
BETTER-B is an HORIZON2020 funded study involving international breathlessness experts from respiratory, palliative care and rehabilitative specialisms. The project will test whether an antidepressant can be repurposed to help in managing breathlessness where non-drug treatments cannot be effectively used. ELF is involved in communication and dissemination together with the ERS.
The EU-funded FAIR project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome AMR in pneumonia. The research focuses on the unique immunomodulator flagellin that enhances airway epithelial innate immune defences, and the development of airway-specific aerosol delivery by nebulisation. ELF is involved in communication and dissemination together with the ERS.
UNITE4TB is the newest project of the IMI AMR Accelerator, a public-private collaboration with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections. The 7-year, project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
OPTIMA is an Innovative Medicines Initiative (IMI)-funded EU project aiming to ensure that every patient with lung, prostate and breast cancer has access to the most up-to-date individualised treatments and innovative therapies. It will do this by strengthening shared decision-making using dynamic computer-interpretable guidelines, and using AI-driven technology and tools.
EUREST-RISE is a project that includes a series of research studies. The studies will make it easier for researchers to examine tobacco products, specifically:
ELF will be offering training on communicating research to policymakers/stakeholders, peer scientists, the general public and the media. Specific objectives are to:
EU REST RISE is funded by European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101008139.
Find out about projects we have worked on in the past that have now ended. Here you can read about what they did and what they learned.
